Clinical trial • Other
MORPHINE SULFATE for Postoperative pain following major laparoscopic abdominal surgery
Clinical trial of MORPHINE SULFATE for Postoperative pain following major laparoscopic abdominal surgery.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Postoperative pain following major laparoscopic abdominal surgery
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 12-09-2025
- First CTIS Authorization Date
- 22-12-2025
Trial design
Randomised, comparator: tramadol (tramadol 100 mg/ml oral drops, solution). test/other arm: morphine (morfinesulfaat sandoz 10 mg tablets and morphine sulfate 10 mg/ml solution for injection). dose and schedule not specified in the ctis record.-controlled trial across 1 site in France.
- Randomised
- Yes
- Comparator
- Comparator: Tramadol (Tramadol 100 mg/ml oral drops, solution). Test/other arm: Morphine (Morfinesulfaat Sandoz 10 mg tablets and Morphine Sulfate 10 mg/ml Solution for Injection). Dose and schedule not specified in the CTIS record.
- Target Sample Size
- 140
- Trial Duration For Participant
- 90
Eligibility
Recruits 140 Vulnerable populations are not selected for inclusion. Patients under legal guardianship, legal protection, or deprived of liberty are explicitly excluded. Consent must be signed by the patient (adults only, Age ≥18). No paediatric assent procedures; study uses adult ICF documents..
- Pregnancy Exclusion
- Pregnant or breastfeeding women
- Vulnerable Population
- Vulnerable populations are not selected for inclusion. Patients under legal guardianship, legal protection, or deprived of liberty are explicitly excluded. Consent must be signed by the patient (adults only, Age ≥18). No paediatric assent procedures; study uses adult ICF documents.
Inclusion criteria
- {"criterion_text":"- Age ≥18 years\n- Scheduled laparoscopic abdominal surgery with an expected operative duration of 2 hours or more\n- Affiliation to the national health insurance system\n- Signed informed consent to participate in the study"}
Exclusion criteria
- {"criterion_text":"- Allergy or intolerance to any of the following medications: paracetamol, nefopam, ketoprofen, tramadol, morphine, sufentanil, lidocaine, propofol, ketamine, dexamethasone, or droperidol\n- Patient unable to self-assess pain using a numerical rating scale (0–10) (e.g., due to language barrier)\n- Pregnant or breastfeeding women\n- Patient under legal guardianship, legal protection, or deprived of liberty\n- Contraindication to any of these medications (refer to the Summary of Product Characteristics): paracetamol, ketoprofen, nefopam, tramadol, morphine, sufentanil, lidocaine, propofol, ketamine, dexamethasone, or droperidol\n- Chronic use of monoamine oxidase inhibitors or CYP2D6 inhibitors\n- Chronic preoperative use of level 2 or 3 analgesics\n- Outpatient surgery\n- Surgery requiring postoperative admission to an intensive care unit (ICU)\n- Patient on long-term oxygen therapy\n- Patient with psychiatric disorders\n- Patient with neurodegenerative diseases"}
Endpoints
Primary endpoints
- {"endpoint_text":"- The primary endpoint is the multidimensional score validated in French assessing postoperative patient recovery: the QoR-15 (Quality of Recovery-15) score at 24 hours after surgery.","definition_or_measurement_approach":"QoR-15 (Quality of Recovery-15) score measured at 24 hours postoperatively (French-validated questionnaire)."}
Secondary endpoints
- {"endpoint_text":"- QoR-15 questionnaire scores at 48 and 72 hours","definition_or_measurement_approach":"QoR-15 score measured at 48 and 72 hours postoperatively."}
- {"endpoint_text":"- Mean postoperative pain NRS (0–10) scores in the Post-Anesthesia Care Unit (PACU), and at 24, 48, and 72 hours","definition_or_measurement_approach":"Pain intensity assessed on an 11-point Numerical Rating Scale (NRS 0–10) in PACU and at 24, 48, 72 hours."}
- {"endpoint_text":"- Opioid consumption expressed in oral morphine equivalent at 24 and 72 hours postoperatively","definition_or_measurement_approach":"Total opioid consumption converted to oral morphine equivalents at 24 and 72 hours postoperatively."}
- {"endpoint_text":"- Analgesic efficacy after opioid administration, assessed by NRS (0–10) two hours post opioid administration","definition_or_measurement_approach":"NRS (0–10) assessed 2 hours after opioid administration to evaluate analgesic efficacy."}
- {"endpoint_text":"- Length of stay in the PACU (minutes) and total postoperative hospital stay (days)","definition_or_measurement_approach":"Duration in PACU measured in minutes; total postoperative hospital length of stay measured in days."}
- {"endpoint_text":"- Occurrence of the following adverse effects after opioid use: nausea/vomiting, ileus, hypoxemia, pruritus, confusion (assessed by CAM tool)","definition_or_measurement_approach":"Incidence of listed opioid-related adverse events within 72 hours postoperatively; confusion assessed using the CAM tool."}
- {"endpoint_text":"- Pain management satisfaction score, evaluated on a numerical scale from 0 to 10 (0 = total dissatisfaction, 10 = total satisfaction) at hospital discharge","definition_or_measurement_approach":"Patient-reported satisfaction score (0–10) at hospital discharge."}
- {"endpoint_text":"- Number of patients consuming opioids daily at 1 and 3 months post-discharge","definition_or_measurement_approach":"Count of patients reporting daily opioid consumption at 1 and 3 months after discharge."}
- {"endpoint_text":"- Misuse risk assessment using the POMI-5F scale","definition_or_measurement_approach":"Risk of misuse evaluated with the POMI-5F questionnaire."}
- {"endpoint_text":"- Presence of chronic post-surgical pain at 3 months after surgery","definition_or_measurement_approach":"Assessment of presence of chronic post-surgical pain at 3 months post-surgery."}
Recruitment
- Planned Sample Size
- 140
- Recruitment Window Months
- 31
- Consent Approach
- Signed informed consent must be provided by the patient (adult). Subject information and ICF Adults (L1_SIS and ICF Adults) are provided; study enrols adults (Age ≥18). Documentation includes French-language translations of protocol materials.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 140
France
- Earliest CTIS Part Ii Submission Date
- 18-11-2025
- Latest Decision Or Authorization Date
- 22-12-2025
- Processing Time Days
- 34
- Number Of Sites
- 1
- Number Of Participants
- 140
Sites
- Site Name
- Centre Hospitalier Universitaire Amiens Picardie
- Department Name
- Anesthesia
- Principal Investigator Name
- Paul TARPIN
- Principal Investigator Email
- tarpin.paul@chu-amiens.fr
- Contact Person Name
- Paul TARPIN
- Contact Person Email
- tarpin.paul@chu-amiens.fr
- Number Of Participants
- 140
Sponsor
Primary sponsor
- Full Name
- Centre Hospitalier Universitaire Amiens Picardie
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- Morphine Sulfate 10mg /ml Solution for Injection
- Active Substance
- MORPHINE SULFATE
- Modality
- Small molecule
- Routes Of Administration
- INTRAVENOUS ADMINISTRATION
- Route
- INTRAVENOUS ADMINISTRATION
- Authorisation Status
- Authorised
- Maximum Dose
- 60 mg per day
- Investigational Product Name
- Morfinesulfaat Sandoz 10 mg, tabletten
- Active Substance
- MORPHINE SULFATE
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- ORAL USE
- Authorisation Status
- Authorised
- Maximum Dose
- 60 mg per day
- Investigational Product Name
- Tramadol 100 mg/ml oral drops, solution.
- Active Substance
- TRAMADOL
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- ORAL USE
- Authorisation Status
- Authorised
- Maximum Dose
- 400 mg per day
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.